The "Valley of Death" is just a box with no exit. We built the door. In Pharma, 90% of the genius happens in the lab. But 90% of the failure happens on the way to the shelf. At MED, we don’t R&D new molecules. We R&D the pathway to market. We’ve heard the advice to "think outside the box" to disrupt healthcare. But when you’re dealing with the FDA, Patient Data Privacy, and complex supply chains, "outside the box" is where products go to die in regulatory limbo. We Think Insi

A new blueprint for unlocking drug adoption in emerging markets Pharma companies or Sponsor Clients entering Emerging Asia Pacific face the same persistent challenge: patients want treatment, hospitals want to provide it, but affordability blocks the pathway . Yet despite the scale of the problem, market-access implementation has barely changed in decades. Programs remain: Slow to localize Fragmented across agencies Dependent on manual assessment High-risk in terms of complia

[Singapore] – [August 1st, 2023] – Medscore , a pioneering healthcare technology company, is committed to transforming the landscape of cancer care in emerging markets. By leveraging advanced means testing software, Medscore empowers patients with cancer and rare diseases to access critical, life-saving treatments that were once out of reach due to affordability challenges ​ The Critical Role of Means Testing to revolutionize access to break-through treatment in emerging mark

​ [Hanoi, Vietnam] – [December 28, 2023] – MedScore, a leading software provider of patient access solutions, today received approval from the Vietnam Ministry of Health for its innovative cancer patient access programs offered by global pharmaceutical sponsor company.   The program leverages MedScore's innovative scoring solution (Means Testing) with geo-location intelligence and banking-level underwriting to digitally assess patients across emerging markets, ensuring they r